Bicuspid Aortic Valve & TAVR: What Heart Patients Need to Know
"Considering transcatheter aortic valve replacement? Learn how imaging ensures the best outcome for those with bicuspid aortic valves."
If you've been diagnosed with a bicuspid aortic valve (BAV) and are exploring treatment options for aortic stenosis, you're likely wondering about transcatheter aortic valve replacement (TAVR). Unlike a normal aortic valve, which has three leaflets, a BAV has only two. This difference can create unique challenges when considering TAVR, a minimally invasive procedure to replace a narrowed aortic valve.
While TAVR is a well-established treatment for severe aortic stenosis in patients at high risk from traditional surgery, most landmark trials excluded those with BAVs. Now, with growing experience and newer generation devices, TAVR is increasingly being considered for BAV patients. However, BAVs are highly variable, and careful planning is essential for success. That’s where imaging comes in.
This article will walk you through exactly what imaging techniques are used, and why they're so important, in determining if TAVR is the right choice for BAV-related aortic stenosis. We will also help you understand what the images tell your doctors, so you can be an informed participant in your heart care.
Evidence on Outcomes and Risk
The evidence summarized here focuses on procedural outcomes rather than a population-wide prevalence estimate. A 2023 JACC review notes that only one study, by Yoon et al., reported increased procedural complications and mortality with TAVR in bicuspid aortic stenosis. That report associated the increased risk with type I anatomy combining excessive leaflet calcification and a calcified raphe; a separate JACC Advances figure compares major bleeding rates after TAVR versus surgical aortic valve replacement in bicuspid stenosis.
Surgery, TAVI, and Planning Challenges
A June 25, 2026 Frontiers article describes aortic stenosis as treatable with surgery or transcatheter aortic valve implantation (TAVI) and sets out to compare the approaches. It notes that bicuspid aortic valve anatomy presents unique challenges that may affect procedural outcomes. A 2021 Circulation review highlights computed tomography’s role in BAV diagnosis and classification and in planning TAVR, while identifying critical knowledge gaps in its use for these patients.
TAVR’s Development
A review in Heart explains that accurate measurements of the aortic annulus diameter and perimeter are needed before implantation to select the appropriate valve size. A 2014 review traces TAVR’s history through its first studies in animal models and humans. It also discusses technological advances, current limitations, and future perspectives in the field.
Mapping Your Heart: The Role of Imaging in BAV and TAVR Decisions
Before TAVR can even be considered, doctors need a detailed map of your aortic valve and the surrounding structures. This isn't just about seeing the two leaflets of the BAV; it's about understanding the valve's unique shape, the amount and location of calcium buildup, and the dimensions of your aorta. Multimodality imaging is crucial for patient selection and device choice.
- Valve Configuration: Is your BAV truly a two-leaflet valve, or are there partial fusions (raphe) that create a more complex picture? Echocardiography, MDCT (multidetector row computed tomography), and MRI all play a role here.
- Calcium Load: Where is the calcium located on your valve? Is it symmetrical or asymmetrical? Cardiac CT is the gold standard for assessing this. Too much calcium, or calcium in the wrong place, can affect how well the TAVR valve expands and seals.
- Aortic Annulus Size and Shape: The aortic annulus is the ring where the valve sits. Precise measurements are critical for choosing the right size TAVR valve. MDCT and 3DTEE (3-dimensional transesophageal echocardiography) are used for this.
- Aortic Root and Ascending Aorta: BAVs are often associated with aortopathy – enlargement of the aorta. Imaging helps determine if your aorta is also dilated and whether it needs to be addressed at the same time as the valve. MDCT and MRI are key here.
- Coronary Artery Height: How far are the openings to your coronary arteries from the aortic valve? If they're too close, the TAVR valve could block them. MDCT helps assess this risk.
Recent Evidence and Trial Results
A systematic review and meta-analysis reports that previously published systematic reviews found new permanent pacemaker implantation rates of 12.2–18.5%, major bleeding rates of 4.2–20.0%, acute kidney injury risks of 2.04–6.50%, and major vascular complication rates of 1.3–8.5% after TAVR in BAV populations. In the three-year NOTION-2 follow-up, patients with bicuspid stenosis had a statistically nonsignificant higher risk with TAVR than SAVR: 20.4% versus 7.8% (hazard ratio 2.9; 95% CI, 0.9–9.0). The same trial snippet reports similar rates in tricuspid stenosis, 14.5% versus 14.4%.
Anatomical Risk and Evidence Gaps
A study of TAVR in bicuspid aortic stenosis used only balloon-expandable valves and notes that these valves have presented a higher annular-rupture risk than self-expanding valves, although rupture did not occur in that study. The study also says previous research found no difference in short- and mid-term TAVR outcomes between the valve types. Separately, a study comparing TAVR for bicuspid versus tricuspid stenosis identifies potential selection bias and the lack of a surgically treated bicuspid control group, and says randomized trials are needed to assess TAVR’s efficacy and safety in bicuspid stenosis.
Bicuspid and Tricuspid Outcomes
A report from the STS/ACC Transcatheter Valve Therapy Registry found device success with current-generation devices was 96.3% in bicuspid versus 97.4% in tricuspid aortic valves (P=0.07). Residual moderate or severe aortic insufficiency was more common in the bicuspid group: 2.7% versus 2.1% (P<0.001). In 75 propensity score-matched cohorts comparing TAVR with SAVR for BAV, 30-day mortality was 1.3% after TAVR and 5.3% after SAVR (p=0.375), while two-year mortality was 9.7% and 18.7%, respectively (p=0.268).
TAVR and BAV: A Promising Future
The good news is that advances in both TAVR valve design and imaging techniques are making TAVR a viable option for more and more BAV patients. Newer generation valves have improved sealing systems and are better able to conform to the often irregular shape of a BAV.
BAV’s Population Impact
A December 2025 review describes bicuspid aortic valve as the most common congenital heart defect. It reports that BAV affects up to 2% of the population. The review also links BAV to increased lifetime risk of aortic stenosis and the need for aortic valve replacement.
These improvements, coupled with detailed pre-procedural planning using MDCT, are leading to excellent outcomes for BAV patients undergoing TAVR. While risks still exist, they are decreasing as the technology and our understanding of BAV anatomy evolve.
If you have a BAV and severe aortic stenosis, talk to your cardiologist about whether TAVR is right for you. Be sure to ask about the imaging techniques they'll use to assess your valve and aorta, and how that information will guide their treatment decisions. By being informed and proactive, you can ensure you receive the best possible care.